ClinicalTrials.gg
CompletedNCT06047548Updated Mar 25, 2026

A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

A Phase 3 interventional study of Tirzepatide and Placebo in Overweight and Obesity, sponsored by Eli Lilly and Company. Completed at 20 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-25.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
441
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 104 studies testing tirzepatide in Obesity — 60 open to participants now, 79 under way, 14 of them phase 3. Tirzepatide · Obesity.

Enrollment
16th of 104
441 · median 69
Started
2023
with 7 others
Phase 3
26 of 104
7 open now
Registered
20th of 104
by date
Lead sponsor
34 of 104
Eli Lilly and Company

Among the 104 studies testing tirzepatide in Obesity, this one is the 16th largest by enrollment, is one of 8 that started in 2023, is one of 26 in phase 3, and was the 20th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

60 of the 104 studies testing tirzepatide in Obesity are open now, in 12 countries. Recruiting first, the newest first:

55 more — sign in →

By country, each count listing its studies:

All 60 open studies →

About tirzepatide

Tirzepatide: first FDA approval 2022 (MOUNJARO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 104 studies testing tirzepatide in Obesity, or all of them as a file.
02

Study summary

The main purpose of this study is to evaluate the efficacy and safety of tirzepatide for the maintenance of body weight reduction.

Read the detailed description

All enrolled participants will complete a 60-week open-label Weight-Loss Period on tirzepatide maximum tolerated dose (MTD) and upon meeting randomization criteria will enter a 52-week double-blinded Weight Maintenance Period to be assigned to either tirzepatide 5 mg, tirzepatide MTD or placebo.

03

Conditions studied

  • Overweight
  • Obesity

Browse trials for

04

In context

Obesity Reclassified

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

This study's enrollment of 441 is above the median of 67 across 9,023 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a (BMI) of ≥30 kilogram/square meter (kg/m²) or ≥27 kg/m² and previously diagnosed with at least 1 of the following weight related comorbidities:

    • Hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease
  • Have a history of at least 1 self-reported unsuccessful dietary effort to lose body weight (BW)

Exclusion criteria

Exclusion Criteria:

  • Have Type 1 Diabetes (T1D) or Type 2 Diabetes (T2D), a history of ketoacidosis, or hyperosmolar state or coma.
  • Have a self-reported change in BW>5 kilogram (kg) within 3 months prior to screening
  • Have a prior or planned surgical treatment for obesity, excluding liposuction or abdominoplasty if performed >1 year prior to screening.
  • Have a history of chronic or acute pancreatitis
  • Have any of the following cardiovascular conditions within 3 months prior to week 0.

    • Acute myocardial infarction, cerebrovascular accident (stroke), unstable angina, and hospitalization due to congestive heart failure (CHF)
    • family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2)
  • History of significant active or unstable major depressive disorder (MDD) or other severe psychiatric disorder within the last 2 years
  • Any lifetime history of a suicide attempt
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
441 participants (actual)

Study arms

  • Experimental
    Tirzepatide 5 milligram (mg)

    Participants will receive tirzepatide subcutaneously (SC).

    Drug: Tirzepatide

  • Experimental
    Tirzepatide Maximum Tolerated Dose

    Participants will receive tirzepatide SC.

    Drug: Tirzepatide

  • Placebo comparator
    Placebo

    Participants will receive placebo.

    Drug: Placebo

Interventions

  • Administered SC

    Also known as: LY3298176

  • DrugPlacebo

    Administered SC

07

What researchers measure

Primary outcomes

  1. Percent Maintenance of Body Weight (BW) Reduction Achieved during the 60-Week Weight Loss Period

    Mean percent maintenance of BW reduction achieved during the 60-Week weight loss period will be measured in participants who have reached a BW plateau.

    Time frame: Week 112

Secondary outcomes

  1. Number of Participants with an Assessment of (yes/no) of Maintaining ≥80% of the BW Reduction Achieved During the 60-week Weight-Loss Period

    Assessment of (yes/no) of maintaining ≥80% of the BW reduction achieved during the 60-week weight loss period will be measured in participants who have reached a BW plateau.

    Time frame: Week 112

  2. Number of Participants with an Assessment of (yes/no) of Maintaining ≥ 15% BW Reduction for Participants Who Have Already Lost ≥15% BW at Randomization

    Assessment of (yes/no) of maintaining ≥15% BW reduction for participants who have already lost ≥15% BW at randomization will be measured in participants who have reached a BW plateau.

    Time frame: Week 112

  3. Percent Change from Baseline in Body Weight

    Time frame: Baseline (Week 0), Week 112

  4. Change from Randomization in Body Weight

    Time frame: Week 60, Week 112

  5. Percent Change from Randomization in Body Weight

    Time frame: Week 60, Week 112

  6. Change from Randomization in Waist Circumference

    Time frame: Week 60, Week 112

  7. Percent Maintenance of BW Reduction Achieved During the 60-week Weight-Loss Period

    Time frame: Week 84

08

Study locations

20 sites
  • Cahaba Research - Pelham
    Pelham, Alabama 35124, United States
  • Velocity Clinical Research, Westlake
    Los Angeles, California 90057, United States
  • Southern California Dermatology, Inc.
    Santa Ana, California 92701, United States
  • Encompass Clinical Research
    Spring Valley, California 91978, United States
  • New Horizon Research Center
    Miami, Florida 33165, United States
  • Oviedo Medical Research
    Oviedo, Florida 32765, United States
  • Rophe Adult and Pediatric Medicine/SKYCRNG
    Union City, Georgia 30291, United States
  • East-West Medical Research Institute
    Honolulu, Hawaii 96814, United States
  • Rocky Mountain Clinical Research
    Idaho Falls, Idaho 83404, United States
  • Asha Clinical Research - Munster
    Hammond, Indiana 46324, United States
  • Iowa Diabetes and Endocrinology Research Center
    West Des Moines, Iowa 50265, United States
  • L-MARC Research Center
    Louisville, Kentucky 40213, United States
  • Prime Health and Wellness/SKYCRNG
    Fayette, Mississippi 39069, United States
  • Alliance for Multispecialty Research, LLC
    Norman, Oklahoma 73069, United States
  • WR-Clinsearch, LLC
    Chattanooga, Tennessee 37397, United States
  • The University of Texas Health Science Center at Houston
    Bellaire, Texas 77401, United States
  • Velocity Clinical Research, Dallas
    Dallas, Texas 75230, United States
  • Southern Endocrinology Associates
    Mesquite, Texas 75149, United States
  • Pinnacle Clinical Research
    San Antonio, Texas 78229, United States
  • Consano Clinical Research, LLC
    Shavano Park, Texas 78231, United States
09

References and documents

Publications

  • Horn DB, Aronne LJ, Wharton S, Bays HE, le Roux CW, Srinath R, Gomez-Valderas E, Arad AD, Das S, Dunn JP, Ribeiro A, Glass LC, Lee CJ. Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2026 Jun 6;407(10545):2305-2318. doi: 10.1016/S0140-6736(26)00656-2. Epub 2026 May 12. PubMed 42119587 ↗
  • Horn DB, Aronne LJ, Wharton S, Bays HE, Gomez-Valderas E, Arad AD, Sharma P, Dunn JP, Senyucel C, Lee CJ. Tirzepatide for the Maintenance of Body Weight Reduction: Rationale, Design, and Baseline Characteristics of SURMOUNT-MAINTAIN. Obesity (Silver Spring). 2025 Oct;33(10):1873-1885. doi: 10.1002/oby.70014. Epub 2025 Sep 7. PubMed 40916045 ↗

Individual participant data

Plan to share: Yes — Anonymized individual participant level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2023 to primary completion in Jan 2026, 28 months.

Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's 28 months is above that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2023
First posted
Sep 21, 2023
StartActual
Sep 20, 2023
Primary completionActual
Jan 20, 2026
CompletionActual
Jan 20, 2026
Last update
Mar 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06047548
Responsible party
Sponsor
First posted
Sep 21, 2023
Start date
Sep 20, 2023
Primary completion
Jan 20, 2026
Completion
Jan 20, 2026
Last update
Mar 25, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tirzepatide

Start the discussion